Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy.
Ploussard G, Terry S, Maillé P, Allory Y, Sirab N, Kheuang L, Soyeux P, Nicolaiew N, Coppolani E, Paule B, Salomon L, Culine S, Buttyan R, Vacherot F, de la Taille A.
Ploussard G, et al. Among authors: paule b.
Cancer Res. 2010 Nov 15;70(22):9253-64. doi: 10.1158/0008-5472.CAN-10-1447. Epub 2010 Nov 2.
Cancer Res. 2010.
PMID: 21045157
Free PMC article.